BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

...facilities: a 310,000-square-foot biologics and advanced therapeutics plant in Boston and a 136,000-square-foot plant for upstream...
BioCentury | Mar 3, 2021
Deals

March 3 Quick Takes: Resilience acquires two manufacturing facilities in North America; plus Agilent-Resolution, AbbVie-Mitokinin, Fusion-Ipsen, LianBio-ReViral and Lava

...biologics and advanced therapeutics Boston plant from Sanofi (Euronext:SAN; NASDAQ:SNY) and a 136,000-square-foot plant for upstream...
BioCentury | Feb 19, 2021
Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

...Inc. President, Chairman and CEO Charles McDermott told BioCentury, “The TLR7 receptor is your body’s most upstream...
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...allows us to interfere in complement activity upstream...
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

...at the intersection between interleukin (IL)-1 family receptors and toll-like receptors (TLRs). The kinase acts upstream...
BioCentury | Dec 4, 2020
Product Development

AZ’s opportunity to expand the severe asthma market with tezepelumab

...eosinophilic phenotype and struggle to control their severe asthma.Upstream...
...all the other biologics work downstream, not upstream.”...
...all the other biologics work downstream, not upstream,”...
BioCentury | Nov 30, 2020
Finance

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

...eosinophilic phenotypes, By targeting JAK, which is farther upstream...
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...positive feedback loops and multiple branch-offs triggering effector functions including inflammation by both C5 and the upstream...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Retrotransposons as acute myelogenous leukemia targets

...In human AML cells, CRISPR-mediated knockout of LTR2B and LTR2 or of an LTR2 insertion upstream...
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

...storm.” Kiran Mazumdar-Shaw, Biocon According to Kiran Mazumdar-Shaw, Alzumab itolizumab’s mechanism of action, which is upstream...
Items per page:
1 - 10 of 566
BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

...facilities: a 310,000-square-foot biologics and advanced therapeutics plant in Boston and a 136,000-square-foot plant for upstream...
BioCentury | Mar 3, 2021
Deals

March 3 Quick Takes: Resilience acquires two manufacturing facilities in North America; plus Agilent-Resolution, AbbVie-Mitokinin, Fusion-Ipsen, LianBio-ReViral and Lava

...biologics and advanced therapeutics Boston plant from Sanofi (Euronext:SAN; NASDAQ:SNY) and a 136,000-square-foot plant for upstream...
BioCentury | Feb 19, 2021
Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

...Inc. President, Chairman and CEO Charles McDermott told BioCentury, “The TLR7 receptor is your body’s most upstream...
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...allows us to interfere in complement activity upstream...
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

...at the intersection between interleukin (IL)-1 family receptors and toll-like receptors (TLRs). The kinase acts upstream...
BioCentury | Dec 4, 2020
Product Development

AZ’s opportunity to expand the severe asthma market with tezepelumab

...eosinophilic phenotype and struggle to control their severe asthma.Upstream...
...all the other biologics work downstream, not upstream.”...
...all the other biologics work downstream, not upstream,”...
BioCentury | Nov 30, 2020
Finance

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

...eosinophilic phenotypes, By targeting JAK, which is farther upstream...
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...positive feedback loops and multiple branch-offs triggering effector functions including inflammation by both C5 and the upstream...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Retrotransposons as acute myelogenous leukemia targets

...In human AML cells, CRISPR-mediated knockout of LTR2B and LTR2 or of an LTR2 insertion upstream...
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

...storm.” Kiran Mazumdar-Shaw, Biocon According to Kiran Mazumdar-Shaw, Alzumab itolizumab’s mechanism of action, which is upstream...
Items per page:
1 - 10 of 566